Back to Authors

Hart, Steven N

0000-0001-7714-2734

Mayo Clinic

Mayo Clinic

Citations 43

The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation
Kocher, Jean-Pierre A., Quest, Daniel, Meiners, Michael A., Moore, Raymond M. , Hossain, Asif, Hart, Steven N. , Dinu, Valentin , Quest, Daniel J, Duffy, Patrick, Rider, David, Duffy, Patrick Emmet , Rider, David A. , Dinu, Valentin , Hart, Steven N , Moore, Raymond

Bioinformatics | March 12, 2014 | Volume: 30 | Issue: 13 | Pages: 1920-1922

10.1093/bioinformatics/btu137 Get It

Abstract Motivation: The Biological Reference Repository (BioR) is a toolkit for annotating variants. BioR stores public and user-specific annotation sources in indexed JSON-encoded flat files (catalogs). The BioR toolkit provides the functionality to combine and retrieve annotation from these catalogs via the command-line interface. Several catalogs from commonly used annotation sources and instructions for creating user-specific catalogs are provided. Commands from the toolkit can be combined with other UNIX commands for advanced annotation processing. We also provide instructions for the development of custom annotation pipelines. Availability and implementation: The package is implemented in Java and makes use of external tools written in Java and Perl. The toolkit can be executed on Mac OS X 10.5 and above or any Linux distribution. The BioR application, quickstart, and user guide documents and many biological examples are available at http://bioinformaticstools.mayo.edu . Contact: Kocher.JeanPierre@mayo.edu Supplementary information: Supplementary data are available at Bioinformatics online.
APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma
Leonard, Brandon , Hart, Steven N. , Burns, Michael B. , Carpenter, Michael A. , Temiz, Nuri A. , Vogel, Rachel I. , Nikas, Jason B. , Brown, William L. , Zhang, Yuji , Maurer, Matthew J. , Oberg, Ann L. , Cunningham, Julie M. , Shridhar, Viji , Bell, Debra A., April, Craig, Bentley, David, Bibikova, Marina, Cheetham, R. Keira, Fan, Jian‐Bing , Grocock, Russell, Humphray, Sean, Kingsbury, Zoya, Peden, John F., Chien, Jeremy , Swisher, Elizabeth M. , Hartmann, Lynn C. , Kalli, Kimberly R., Goode, Ellen L. , Sicotte, Hugues , Rathore, Anurag Singh , Law, Emily K. , Li, Ying , Kaufmann, Scott H. , Harris, Reuben S. , Maurer, Matthew , Chien, Jeremey , Swisher, Elizabeth M , Vogel, Rachel I , Hart, Steven N , Temiz, Nuri A

Cancer Research | October 24, 2013 | Volume: 73 | Issue: 24 | Pages: 7222-7231

10.1158/0008-5472.can-13-1753 Get It

Abstract Ovarian cancer is a clinically and molecularly heterogeneous disease. The driving forces behind this variability are unknown. Here, we report wide variation in the expression of the DNA cytosine deaminase APOBEC3B, with elevated expression in the majority of ovarian cancer cell lines (three SDs above the mean of normal ovarian surface epithelial cells) and high-grade primary ovarian cancers. APOBEC3B is active in the nucleus of several ovarian cancer cell lines and elicits a biochemical preference for deamination of cytosines in 5′-TC dinucleotides. Importantly, examination of whole-genome sequence from 16 ovarian cancers reveals that APOBEC3B expression correlates with total mutation load as well as elevated levels of transversion mutations. In particular, high APOBEC3B expression correlates with C-to-A and C-to-G transversion mutations within 5′-TC dinucleotide motifs in early-stage high-grade serous ovarian cancer genomes, suggesting that APOBEC3B-catalyzed genomic uracil lesions are further processed by downstream DNA "repair" enzymes including error-prone translesion polymerases. These data identify a potential role for APOBEC3B in serous ovarian cancer genomic instability. Cancer Res; 73(24); 7222–31. ©2013 AACR.
Calculating Sample Size Estimates for RNA Sequencing Data
Hart, Steven N. , Therneau, Terry M. , Zhang, Yuji , Kocher, Jean‐Pierre , Poland, Gregory A. , Hart, Steven N

Journal of Computational Biology | August 20, 2013 | Volume: 20 | Issue: 12 | Pages: 970-978

10.1089/cmb.2012.0283 Get It

Abstract Background: Given the high technical reproducibility and orders of magnitude greater resolution than microarrays, next-generation sequencing of mRNA (RNA-Seq) is quickly becoming the de facto standard for measuring levels of gene expression in biological experiments. Two important questions must be taken into consideration when designing a particular experiment, namely, 1) how deep does one need to sequence? and, 2) how many biological replicates are necessary to observe a significant change in expression? Results: Based on the gene expression distributions from 127 RNA-Seq experiments, we find evidence that 91% ± 4% of all annotated genes are sequenced at a frequency of 0.1 times per million bases mapped, regardless of sample source. Based on this observation, and combining this information with other parameters such as biological variation and technical variation that we empirically estimate from our large datasets, we developed a model to estimate the statistical power needed to identify differentially expressed genes from RNA-Seq experiments. Conclusions: Our results provide a needed reference for ensuring RNA-Seq gene expression studies are conducted with the optimally sample size, power, and sequencing depth. We also make available both R code and an Excel worksheet for investigators to calculate for their own experiments.